RECENT NEWS

  • Mar 2024
    We just published a new paper on Lung Cancer entitled “Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer”. doi: 10.1016/j.lungcan.2024.107495.
  • Oct 2023
    We just published a new paper on Eur J Med Chem entitled “Discovery of dihydropyridinone derivative as a covalent EZH2 degrader”. doi: 10.1016/j.ejmech.2023.115825.
  • Sep 2023
    We just published a new paper on Acta Pharm Sin B entitled “Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy”. doi: 10.1016/j.apsb.2023.05.026.
  • Nov 2023
    We just published a new paper on Eur J Med Chem entitled “Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor”. doi: 10.1016/j.ejmech.2023.115768.
  • June 2023
    We just published a new paper on MedComm entitled “Pharmacological inhibiting STAT5 for the treatment of FLT3-ITD-positive acute myeloid leukemia with triciribine phosphate monohydrate”. doi: 10.1002/mco2.294.
  • May 2023
    We just published a new paper on Eur J Med Chem entitled “Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor”. doi: 10.1016/j.ejmech.2023.115411.
  • May 2023
    We just published a new paper on MedComm entitled “Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2”. doi: 10.1002/mco2.254.
  • May 2023
    We just published a new paper on Eur J Pharmacol entitled “Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment”. doi: 10.1016/j.ejphar.2023.175752.
  • Apr 2023
    We just published a new paper on Signal Transduct Target Ther entitled “Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus”. doi: 10.1038/s41392-023-01352-4.
  • Jan 2023
    We just published a new paper on Signal Transduct Target Ther entitled “Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies”. doi: 10.1038/s41392-022-01240-3.
  • Oct 2022
    We just published a new paper on Acta Pharmacol Sin entitled “Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1”. doi: 10.1038/s41401-022-00993-5.
  • Sep 2022
    We just published a new paper on European Journal of Medicinal Chemistry entitled “Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors”. doi: 10.1016/j.ejmech.2022.114782.
  • Sep 2022
    We just published a new paper on J. Med. Chem. entitled “Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes”. doi: 10.1021/acs.jmedchem.2c00926.
  • Aug 2022
    We just published a new paper on MedComm entitled “Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities”. doi: 10.1002/mco2.161.
  • Aug 2022
    We just published a new paper onPharmaceutics entitled “PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML)”. doi: 10.3390/pharmaceutics14081662.
  • Jun 2022
    We just published a new paper on Anal Cell Pathol. entitled “Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations”. doi: 10.1155/2022/2376288.
  • Feb 2022
    We just published a new paper on Acta Pharmacol Sin. entitled “CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers”. doi: 10.1038/s41401-022-00882-x.
  • Fep 2022
    We just published a new paper on Mol. Oncol. entitled “Nintedanib overcomes drug resistance from upregulation of FGFR signaling and imatinib-induced KIT mutations in gastrointestinal stromal tumors”. doi: 10.1002/1878-0261.13199.
  • Jan 2022
    We just published a new paper on Leukemia entitled “Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2”. doi: 10.1038/s41375-021-01494-w.

 

RECENT PUBLICATIONS

152. Yun Wang#, Chen Hu#, Hongwei Yu#, Jie Hu, Zhiwei Zhou, Ning Fu, Xiang Huang, Fanhao Kong, Wenchao Wang*, Jing Liu*, Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer. Lung Cancer , 189 (2024) 107495; doi: 10.1016/j.lungcan.2024.107495.

151. Bin Zhou#, Beilei Wang#, Fengming Zou#, Husheng Mei#, Qingwang Liu, Shuang Qi, Wenliang Wang, Rui Jin, Aoli Wang, Yongfei Chen, Feiyang Liu, Wenchao Wang, Jing Liu*, Qingsong Liu*, Discovery of dihydropyridinone derivative as a covalent EZH2 degrader. Eur J Med Chem , 2023 Oct 2;261:115825; doi: 10.1016/j.ejmech.2023.115825.

150. Chen Hu#, Lijuan Shen#, Fengming Zou#, Yun Wu#, Beilei Wang, Aoli Wang, Chao Wu, Li Wang, Jing Liu*, Wenchao Wang*, Qingsong Liu*, Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy. Acta Pharm Sin B , 2023 Sep;13(9):3694-3707 10.1016/j.apsb.2023.05.026.

149. Xiaofei Liang#, Maoqing Deng#, Fengming Zou#, Ziping Qi#, Chun Wang, Juan Liu, Qingwang Liu, Beilei Wang, Shuang Qi, Juan Ge, Hongwei Yu, Aoli Wang, Qingsong Liu*, Jing Liu*, Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor. Eur J Med Chem , 2023 Nov 15;260:115768; doi: 10.1016/j.ejmech.2023.115768.

148. Hong Wu, Juan Ge, Fengming Zou, Zongru Jiang, Beilei Wang, Xinyu Yuan, Kaili Long, Jing Liu*, Wenchao Wang*, Qingsong Liu*, Pharmacological inhibiting STAT5 for the treatment of FLT3-ITD-positive acute myeloid leukemia with triciribine phosphate monohydrate. MedComm , 2023 June 21;4:e294; doi: 10.1002/mco2.294.

147. Qianmao Liang #, Beilei Wang #, Fengming Zou #, Gongrui Guo #, Wenliang Wang, Wei Wang, Qingwang Liu, Lijuan Shen, Chen Hu, Wenchao Wang, Aoli Wang, Tao Huang, Yuying He, Ruixiang Xia, Jian Ge*, Jing Liu*, Qingsong Liu*, Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor. Eur J Med Chem , 2023 May 12;256:115411; doi: 10.1016/j.ejmech.2023.115411.

146. Yiying Xue, Husheng Mei, Yisa Chen, James D Griffin, Qingsong Liu*, Ellen Weisberg*, Jing Yang*, Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2. MedComm , 2023 May 14;4(3):e254; doi: 10.1002/mco2.254.

145. Aoli Wang #, Juan Liu #, Xixiang Li #, Fengming Zou #, Ziping Qi, Shuang Qi, Qingwang Liu, Zuowei Wang, Jiangyan Cao, Zongru Jiang, Beilei Wang, Juan Ge, Li Wang, Wenchao Wang*, Jing Liu*, Qingsong Liu*, Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment. Eur J Pharmacol , 2023 May 8:175752; doi: 10.1016/j.ejphar.2023.175752.

144. Junjie Wang #, Ziping Qi # , Yun Wu # , Aoli Wang # , Qingwang Liu , Fengming Zou , Beilei Wang , Shuang Qi , Jiangyan Cao , Chen Hu , Chenliang Shi , Qianmao Liang , Li Wang , Jing Liu*, Wenchao Wang* , Qingsong Liu*, Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus. Signal Transduct Target Ther , 2023 Apr 5;8(1):143; doi: 10.1038/s41392-023-01352-4.

143. Husheng Mei # , Hong Wu # , Jing Yang # , Bin Zhou # , Aoli Wang , Chen Hu, Shuang Qi, Zongru Jiang, Fengming Zou, Beilei Wang, Feiyang Liu , Yongfei Chen, Wenchao Wang*, Jing Liu*, Qing-Song Liu*, Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies. Signal Transduct Target Ther , 2023 Jan 16;8(1):18; doi: 10.1038/s41392-022-01240-3.

142. Zuo-Wei Wang# , Feng-Ming Zou# , Ao-Li Wang# , Jing Yang , Rui Jin , Bei-Lei Wang , Li-Juan Shen , Shuang Qi , Juan Liu , Jing Liu* , Wen-Chao Wang *, Qing-Song Liu*, Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1. Acta Pharmacol Sin , 2022 Oct 10; doi: 10.1038/s41401-022-00993-5.

141. Xiaofei Liang#, Chun Wang#, Beilei Wang#, Juan Liu, Shuang Qi, Aoli Wang Qingwang Liu, Maoqing Deng, Li Wang, Jing Liu*,Qingsong Liu*, Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors. European Journal of Medicinal Chemistry  , 2022 Sep 21;doi: 10.1016/j.ejmech.2022.114782.

140. Yun Wu#, Ziping Qi#, Beilei Wang#, Junjie Wang#, Qingwang Liu, Aoli Wang, Chenliang Shi, Bin Zhou, Qianmao Liang, Wenliang Wang, Fengming Zou, Shuang Qi, Zuowei Wang, Li Wang, Wenchao Wang, Jing Liu*, and Qingsong Liu*, Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes. J. Med. Chem. , 2022 Aug 29; 65, 17, 11818–11839;doi: 10.1021/acs.jmedchem.2c00926.

139. Chen Hu, Jing Yang, Ziping Qi, Hong Wu, Beilei Wang, Fengming Zou, Husheng Mei, Jing Liu, Wenchao Wang*, Qingsong Liu*, Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities. MedComm, 2022 Aug 2;doi: 10.1002/mco2.161.

138. Huamin Liang#, Fengming Zou#, Liyi Fu, Qingwang Liu, Beilei Wang, Xiaofei Liang, Jing Liu*, Qing-Song Liu*, PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML). Pharmaceutics, 2022 Aug 10;doi: 10.3390/pharmaceutics14081662.

137. Chuan-Dong Cheng, Cheng Chen, Li Wang, Yong-Fei Dong, Yang Yang, Yi-Nan Chen, Wan-Xiang Niu, Wen-Chao Wang*, Qing-Song Liu*, Chao-Shi Niu*, Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations. Anal Cell Pathol., 2022 Jun 15;doi: 10.1155/2022/2376288.

136. Jiang-Yan Cao# , Shuang Qi# , Hong Wu# , Ao-Li Wang , Qing-Wang Liu, Xi-Xiang Li, Bei-Lei Wang, Juan Ge, Feng-Ming Zou, Cheng Chen , Jun-Jie Wang, Chen Hu, Jing Liu*, Wen-Chao Wang*, Qing-Song Liu*, CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers. Acta Pharmacol Sin., 2022 Feb 28;doi: 10.1038/s41401-022-00882-x.

135. Juan Liu#, Jingjing Gao#, Aoli Wang#, Zongru Jiang#, Shuang Qi, Ziping Qi, Feiyang Liu, Kailin Yu, Jiangyan Cao, Cheng Chen， Chen Hu, Hong Wu , Li Wang , Wenchao Wang, Qingsong Liu*, Jing Liu*， Nintedanib overcomes drug resistance from upregulation of FGFR signaling and imatinib-induced KIT mutations in gastrointestinal stromal tumors. Mol. Oncol., 2022 Feb 23;doi: 10.1002/1878-0261.13199.

134. Jing Yang #, Ellen L Weisberg # , Shuang Qi # , Wei Ni , Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S Magin, Laura Doherty , Wenchao Wang Jing Liu, Sara J Buhrlage*, Qingsong Liu*, James D Griffin*. Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia, 2022 Jan 17;doi: 10.1038/s41375-021-01494-w.

133. Beilei Wang# , Hong Wu , Chen Hu , Haizhen Wang , Jing Liu , Wenchao Wang, Qingsong Liu*. An overview of kinase downregulators and recent advances in discovery approaches. Signal Transduct Target Ther., 2021 Dec 20;6(1):423;doi: 10.1038/s41392-021-00826-7.

132. Bin Zhou#, Xiaofei Liang# , Husheng Mei#, Shuang Qi#, Zongru Jiang, Aoli Wang, Fengming Zou, Qingwang Liu, Juan Liu, Wenliang Wang, Chen Hu, Yongfei Chen, Zuowei Wang, Beilei Wang, Li Wang, Jing Liu*, and Qingsong Liu*. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. J. Med.Chem., 2021 Oct 19.;doi: 10.1021/acs.jmedchem.1c01154.

131. Chen Hu #, Fengming Zou #, Aoli Wang #, Weili Miao, Qianmao Liang, Ellen L Weisberg, Yinsheng Wang, Jing Liu*, Wenchao Wang*, Qingsong Liu*. Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia. Signal Transduct Target Ther., 2021 Sep 15;6(1):334;doi: 10.1038/s41392-021-00672-7.

130. Huamin Liang#, Fengming Zou#, Qingwang Liu#, Beilei Wang#, Liyi Fu , Xiaofei Liang, Jing Liu*, Qingsong Liu*. Nanocrystal-loaded liposome for targeted delivery of poorly water-soluble antitumor drugs with high drug loading and stability towards efficient cancer therapy. Int J Pharm., 2021 Feb 26;120418., doi: 10.1016/j.ijpharm.2021.120418.

129. Tingting Lu#, Jiangyan Cao #, Fengming Zou #, Xixiang Li , Aoli Wang , Wenliang Wang , Huamin Liang , Qingwang Liu , Chen Hu , Cheng Chen , Zhenquan Hu , Wenchao Wang , Lili Li , Jian Ge , Yang Shen , Tao Ren , Jing Liu , Ruixiang Xia*, Qingsong Liu*. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Eur J Pharmacol., 2021 Feb 10;173944., doi: 10.1016/j.ejphar.2021.173944.

128. Lei Zhu #, Hongxin Zhao #, Juanjuan Liu #, Hao Cai , Bo Wu , Zhijun Liu , Shu Zhou , Qingsong Liu , Xiaokun Li, Bin Bao , Jian Liu , Han Dai*. Dynamic folding modulation generates FGF21 variant against diabetes. EMBO Rep., 2020 Dec9;e51352 , doi: 10.15252/embr.202051352.

127. Fan Song#, Zhen Qi#, Chen Cheng#, Wang Wenjun#, Wu Qibing#, Ma Huihui, Zhang Chengyuan, Zhang Li, Lu Baojing, Ge Huiyao, Yong Liang, Li Bao, Yu Yafen, Chen Weiwei, Mao Yiwen, Qu Guangbo, Su Li, Wang Aoli, Ding Zhen, Li Haiwen, Zhang Jin, Wang Yonglian, Gao Yufeng, Xu Xihai, Zhu Zhongming, Chen Jun, Zhang Long, Liang Hongqiang, Wu Song, Huang Meng, Xia Quan, Li Ping, Sun Yehuan, Liang Chaozhao, Wei Wei*, Liu Qingsong*, Sun Liangdan*. Clinical efficacy of low-dose emetine for patients with COVID-19 a real-world study. Journal of Bio-X Research, 2020 Dec , doi: 10.1097/JBR.0000000000000076.

126. Aoli Wang#, Yong Sun#, Qingwang Liu#, Hong Wu#, Juan Liu#, Jun He, Junling Yu, Qing Qing Chen, Yinglu Ge, Zhuhui Zhang, Chen Hu, Cheng Chen, Ziping Q, Fengming Zou, Feiyang Liu, Jie Hu, Ming Zhao, Tao Huang, Beilei Wang, Li Wang, Wei Wang, Wenchao Wang, Tao Ren, Jing Liu, Yehuan Sun, Song Fan, Qibing Wu, Chaozhao Liang, Liangdan Sun*, Bin Su*, Wei Wei* and Qingsong Liu*. Low dose of emetine as potential antiSARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences. Molecular Biomedicine, 2020 Dec , doi: 10.1186/s43556-020-00018-9.

125. Feng Li#, Xiaofei Liang#, Zongru Jiang#, Aoli Wang#, Junjie Wang, Cheng Chen, Wenliang Wang, Fengming Zou, Ziping Qi, Qingwang Liu, Zhenquan Hu, Jiangyan Cao, Hong Wu, Beilei Wang, Li Wang, Jing Liu*, and Qingsong Liu*. Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. J. Med.Chem. 2020 Nov 12 , doi: 10.1021/acs.jmedchem.0c01544.

124. Zi Ye #, Yankun Wang #, Hong Wu #, Tong Song , Xixiang Li , Qingsong Liu *, Chu Wang *. Chemoproteomic profiling of an Ibrutinib analogue reveals its unexpected role in DNA damage repair. Chembiochem, 2020 Sep 26 , doi: 10.1002/cbic.202000527.

123. Juan Liu#, Qianmao Liang#, Aoli Wang#, Fengming Zou#, Ziping Qi, Kailin Yu, Qingwang Liu, Cheng Chen, Jing Liu*, Qingsong Liu*. Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma. Signal Transduction and Targeted Therapy, 2020 Sep 14;5(1):200 , doi: 10.1038/s41392-020-00309-1.

122. Beilei Wang#, Wentao Zhang#, Xuesong Liu#, Fengming Zou#, Junjie Wang, Qingwang Liu, Aoli Wang, Zhenquan Hu, Yongfei Chen, Shuang Qi, Zongru Jiang, Cheng Chen, Chen Hu, Li Wang, Wenchao Wang, Qingsong Liu*, Jing Liu*. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a Novel Orally Available Type II TRK Kinase Inhibitor Capable of Overcoming Multiple Resistant Mutants. Eur. J. Med. Chem. , Available online 30 Auguest 2020 , doi: 10.1016/j.ejmech.2020.112744.

121. Liyi Fu #, Fengming Zou #, Qingwang Liu , Beilei Wang , Junqing Wang , Huamin Liang , Xiaofei Liang , Jing Liu , Jinjun Shi *, Qingsong Liu* . An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia. Nanomedicine , 2020 Aug 7;102283 , doi: 10.1016/j.nano.2020.102283.

120. Ellen Weisberg#*, Alexander Parent , Priscilla L Yang , Martin Sattler , QingsongLiu , Qingwang Liu , Jinhua Wang , Chengcheng Meng , Sara J Buhrlage , Nathanael Gray , James D Griffin. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res. , 2020 Aug 10;37(9):167, doi: 10.1007/s11095-020-02851-7.

119. Wen-Liang Wang#, Zong-Ru Jiang#, Chen Hu , Cheng Chen , Zhen-Quan Hu, Ao-Li Wang , Li Wang , Jing Liu*, Wen-Chao Wang*, Qing-Song Liu* . Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52. Acta Pharmacologica Sinica , 2020 Jul 31, doi: 10.1038/s41401-020-0465-8.

118. Cheng Chen#, Chuan-dong Cheng#, Hong Wu#, Zuo-wei Wang#, Li Wang, Zong-ru Jiang, Ao-li Wang, Chen Hu, Yong-fei Dong, Wan-xiang Niu, Shuang Qi, Zi-ping Qi, Jing Liu, Wen-chao Wang*, Chao-shi Niu* ,Qing-song Liu* . Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. Acta Pharmacologica Sinica , 2020 May 12, doi: 10.1038/s41401-020-0418-2.

117. Cheng Chen#, Li Wang#, Lili Li#, Aoli Wang, Tao Huang, Jie Hu, Ming Zhao, Feiyang Liu, Shuang Qi, Chen Hu, Wenliang Wang, Jing Liu, Jian Ge, Ruixiang Xia*, Wenchao Wang*, Qingsong Liu* . Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. Experimental Cell Research , 2020 May 3, doi: 10.1016/j.yexcr.2020.112054.

116. Aoli Wang#, Chen Hu#, Cheng Chen#, Xiaofei Liang#, Beilei Wang#, Fengming Zou, Kailin Yu, Feng Li, Qingwang Liu, Ziping Qi, Junjie Wang, Wenliang Wang, Li Wang, Ellen L. Weisberg, Wenchao Wang, Lili Li, Jian Ge, Ruixiang Xia, Jing Liu*, Qingsong Liu* . Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia. Haematologica , 2020 Apr 16. pii: haematol., doi: 10.3324/haematol.2019.244186.

115. Wenliang Wang#, Zongru Jiang#, Li Wang#, Aoli Wang#, Juan Liu, Cheng Chen, Kailin Yu, Fengming Zou, Wenchao Wang*, Jing Liu*, Qingsong Liu*. All-Trans Retinoic Acid Exerts Selective Anti-FLT3-ITD Acute myeloid leukemia Efficacy through Downregulating Chk1 Kinase. Cancer Letters , Available online 2 January 2020, doi: 10.1016/j.canlet.2019.12.045.

114. Xiaofei Liang#, Zongru Jiang#, Zhenghui Huang#, Feng Li#, Cheng Chen, Chen Hu, Wenliang Wang, Zhenquan Hu, Qingwang Liu, Beilei Wang, Li Wang, Ziping Qi, Jing Liu*, Lubin Jiang*, Qingsong Liu*.Discovery of 6′-chloro-N-methyl-5'-(phenylsulfonamido)-[3,3′-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium. European Journal of Medicinal Chemistry , Available online 27 December 2019, doi: 10.1016/j.ejmech.2019.112012.

113. Li Wang#, Chen Hu#, Aoli Wang#, Cheng Chen#, Jiaxin Wu#, Zongru Jiang, Fengming Zou, Kailin Yu, Hong Wu, Juan Liu, Wenliang Wang, Zuowei Wang, Beilei Wang, Ziping Qi, Qingwang Liu, Wenchao Wang, Lili Li, Jian Ge*Jing Liu* , Qingsong Liu*.Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models. Invest New Drugs , 2019 Dec 23, doi: 10.1007/s10637-019-00868-3.

112. Sameer S.Chopra, Anne Jenney, Adam Palmer, MarioNiepel, MirraChung, CaitlinMills, Sindhu Carmen, Sivakumaren, QingsongLiu, Jia-YunChen, ClarenceYapp, John M.Asara, Nathanael S.Gray, Peter K.Sorger.Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. Cell Syst. , 2019 Dec 2. pii: S2405-4712(19)30387-4,doi: 10.1016/j.cels.2019.11.001.

111. Zongru Jiang #, Li Wang#, Xuesong Liu#, Cheng Chen#, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu, Ziping Qi, Qingwang Liu, Aoli Wang, Jing Liu, Guangchen Hong*, Wenchao Wang*, Qingsong Liu*. Discovery of a Highly Selective VEGFR2 Kinase Inhibitor CHMFL-VEGFR2-002 as a Novel Anti-angiogenesis Agent. Acta Pharmaceutica Sinica B, 2019, doi: 10.1016/j.apsb.2019.10.004.

110. Yun Wu#, Beilei Wang#, Junjie Wang#, Shuang Qi#, Fengming Zou, Ziping Qi, Feiyang Liu, Qingwang Liu, Cheng Chen, Chen Hu, Zhenquan Hu, Aoli Wang, Li Wang, Wenchao Wang, Tao Ren, Yujiao Cai, Mingfeng Bai, Qingsong Liu*, Jing Liu*. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. J. Med. Chem. 2019, Jun 28. doi: 10.1021/acs.jmedchem.9b00280

109. Feiyang Liu#, Fengming Zou#, Cheng Chen#, Kailin Yu#, Xiaochuan Liu, Shuang Qi, Jiaxin Wu, Chen Hu, Zhenquan Hu, Juan Liu, Xuesong Liu, Li Wang, Juan Ge, Wenchao Wang, Tao Ren, Mingfeng Bai, Yujiao Cai, Xudong Xiao, Feng Qian, Jun Tang*, Qingsong Liu*, Jing Liu*. Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors. Ther Adv Med Oncol. First Published May 17, 2019 Research Article, doi: 10.1177/1758835919849757

108. Xuesong Liu#, Beilei Wang#, Cheng Chen#, Ziping Qi#, Fengming Zou, Junjie Wang, Chen Hu, Aoli Wang, Juan Ge, Qingwang Liu, Kailin Yu, Zhenquan Hu, Zongru Jiang, Wei Wang, Li Wang, Wenchao Wang, Tao Ren, Mingfeng Bai, Qingsong Liu*, and Jing Liu*. Discovery of (E)-N1-(3-fluorophenyl)-N3-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). J. Med.Chem. Publication Date (Web): May 2, 2019 (Article), doi: 10.1021/acs.jmedchem.9b00176

107. Qi Wang#, Zhenquan Hu, Xiangchao Luo, Jing Liu , Guoqiang Li*, Shugeng Cao* , and Qingsong Liu*. Clavukoellians A–F, Highly Rearranged Nardosinane Sesquiterpenoids with Antiangiogenic Activity from Clavularia koellikeri. J. Nat. Prod. April 17, 2019, doi: 10.1021/acs.jnatprod.9b00100

106. Shun Li#, Ying Song, Christine Quach, Hongrui Guo, Gyu-Beom Jang, Hadi Maazi, Shihui Zhao, Nathaniel A. Sands, Qingsong Liu, Gino K. In, David Peng, Weiming Yuan, Keigo Machida, Min Yu, Omid Akbari, Ashley Hagiya, Yongfei Yang, Vasu Punj, Liling Tang* & Chengyu Liang* . Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019 Apr 12;10(1):1693. doi: 10.1038/s41467-019-09634-8.

105. Lei Gao#, Yong Hu, Yahui Tian, Zhenzhen Fan, Kun Wang, Hongdan Li, Qian Zhou, Guandi Zeng, Xin Hu, Lei Yu, Shiyu Zhou, Xinyuan Tong, Hsinyi Huang, Haiquan Chen, Qingsong Liu, Wanting Liu, Gong Zhang, Musheng Zeng, Guangbiao Zhou, Qingyu He*, Hongbin Ji* & Liang Chen* . Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition. Nat Commun. 2019 Apr 10;10(1):1665. doi: 10.1038/s41467-019-09295-7.

104. Jiaxin Wu#, Aoli Wang#, Xixiang Li#, Cheng Chen#, Ziping Qi#, Chen Hu, Wenliang Wang, Hong Wu, Tao Huang, Ming Zhao, Wenchao Wang, Zhenquan Hu, Qingwang Liu, Beilei Wang, Li Wang, Lili Li, Jian Ge, Tao Ren, Ruixiang Xia*, Jing Liu* & Qingsong Liu*. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML). Cancer Biol Ther. 2019 Mar 20:1-9; doi: 10.1080/15384047.2019.1579958. [Epub ahead of print].

103. Rui-Yuan Pan#, Jun Ma, Xiang-Xi Kong, Xiao-Feng Wang, Shuo-Shuo Li, Xiao-Long Qi, Yu-Han Yan, Jinbo Cheng, Qingsong Liu, Wanzhu Jin, Chang-Heng Tan and Zengqiang Yuan*. Sodium rutin ameliorates Alzheimer's disease-like pathology by enhancing microglial amyloid-β clearance. Sci Adv. 2019 Feb; 5(2): eaau6328. doi: 10.1126/sciadv.aau6328.

102. Tingting Lu#, Cheng Chen#, Aoli Wang#, Zongru Jiang#, Ziping Qi, Zhenquan Hu, Chen Hu, Feiyang Liu, Wenliang Wang, Hong Wu, Beilei Wang, Li Wang, Shuang Qi, Jiaxin Wu, Wenchao Wang, Jun Tang, Hezhong Yan, Mingfeng Bai, Qingsong Liu*, Jing Liu*. Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models. Cancer Lett. 2019, Jan 23. pii: S0304-3835(19)30044-8. doi: 10.1016/j.canlet.2019.01.024.

101. Chunshun Li# , Ariel M. Sarotti , Xiaohua Wu , Baojun Yang , James Turkson , Yongfei Chen , Qingsong Liu and Shugeng Cao*. An Unusual Benzoisoquinoline-9-one Derivative and Other Related Compounds with Antiproliferative Activity from Hawaiian Endophytic Fungus Peyronellaea sp. FT431. Molecules. 2019, 24(1), 196; doi: 10.3390/molecules24010196

100. Xiaofei Liang#, Beilei Wang#, Cheng Chen#, Aoli Wang#, Chen Hu, Fengming Zou, Kailin Yu, Qingwang Liu, Feng Li, Zhenquan Hu, Tingting Lu, Junjie Wang, Li Wang, Ellen Weisberg, Lili Li, Ruixiang Xia, Wenchao Wang, Tao Ren, Jian Ge*, Jing Liu*, and Qingsong Liu*. Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent Fms-like Tyrosine Kinase 3 Internal Tandem Duplications (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. J. Med. Chem. Publication Date (Web): December 19, 2018 (Article), doi: 10.1021/acs.jmedchem.8b01594

99. Qi Wang#, Zhenquan Hu, Xixiang Li, Aoli Wang, Hong Wu, Jing Liu, Shugeng Cao*, and Qingsong Liu*. Salviachinensines A–F, Antiproliferative Phenolic Derivatives from the Chinese Medicinal Plant Salvia chinensis. J. Nat. Prod. Article Publication Date (Web): October 29, 2018, doi: 10.1021/acs.jnatprod.8b00638

98. Xuesong Liu#, Beilei Wang#, Cheng Chen#, Zongru Jiang#, Chen Hu, Hong Wu, Yicong Zhang, Xiaochuan Liu, Wenliang Wang, Junjie Wang, Zhenquan Hu, Aoli Wang, Tao Huang, Qingwang Liu, Wei Wang, Li Wang, Wenchao Wang, Tao Ren, Lili Li, Ruixiang Xia, Jian Ge*, Qingsong Liu*, Jing Liu*. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. Eur. J. Med. Chem. 2018, in press doi: 10.1016/j.ejmech.2018.10.007

97. Beilei Wang#, Jiaxin Wu#, Yun Wu#, Cheng Chen#, Fengming Zou#, Aoli Wang, Hong Wu, Zhenquan Hu, Zongru Jiang, Qingwang Liu, Wei Wang, Yicong Zhang, Feiyang Liu, Ming Zhao, Jie Hu, Tao Hu, Juan Ge, Li Wang, Tao Ren, Yuxin Wang, Jing Liu*, Qingsong Liu*. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor Eur. J. Med. Chem. 2018, in press doi: 10.1016/j.ejmech.2018.09.025

96. Chunshun Li, Zhenquan Hu, Qingsong Liu, Xiaohua Wu, Shugeng Cao*. Two new tricycloalternarenes from Hawaiian endophytic fungus Didymella sp. FT433. Tetrahedron Lett. 2018, 59: 3381-3383. doi: 10.1016/j.tetlet.2018.07.061

95. Ke Deng, Jiawei Shen, Wei Wang, Ming Li, Hong Li, Cheng Chen, Huan Zhao, Mei Zhang, Tian Xue, Qingsong Liu, Vivian Was Yan Lui, Bo Hong*, Wenchu Lin*. Sodium chloride(NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer. Cancer Biol. Ther. 2018, 5: 1-13. doi: 10.1080/15384047.2018.1504723

94. Xiaofei Liang#, Feng Li#, Cheng Chen#, Zongru Jiang#, Aoli Wang#, Xiaochuan Liua, Juan Ge, Zhenquan Hu, Kailin Yu, Wenliang Wang, Fengming Zou, Qingwang Liu, Beilei Wang, Li Wang, Shanchun Zhang, Yuxin Wang, Qingsong Liu*, Jing Liu*. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3- methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3- methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kd) inhibitor. Eur. J. Med. Chem. 2018, 156: 831-846. doi: 10.1016/j.ejmech.2018.07.036

93. Hongbin He#, Hua Jiang, Yun Chen, Jin Ye, Aoli Wang, Chao Wang, Qingsong Liu, Gaolin Liang, Xianming Deng*, Wei Jiang* & Rongbin Zhou*.Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nature Communications. 2018 Jun 29;9(1):2550. doi: 10.1038/s41467-018-04947-6. [Epub ahead of print]

92. Yu Xue#, Peiran Song#, Zilan Song#, Aoli Wang, Linjiang Tong, Meiyu Geng, Jian Ding, Qingsong Liu , Liping Sun, Hua Xie*, and Ao Zhang*.Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors. J. Med. Chem.2018 May 9; doi: 10.1021/acs.jmedchem.8b00441. [Epub ahead of print]

91. Qiang Wang#, Feiyang Liu#, Shuang Qi#, Ziping Qi#, Xiao-E Yan, Beilei Wang, Aoli Wang, Wei Wang, Cheng Chen, Xiaochuan Liu, Zongru Jiang, Zhenquan Hu, Li Wang, Wenchao Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Qingsong Liu*, Jing Liu*.Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia. Eur. J. Med. Chem. 2018 Mar 12;150:366-384. doi: 10.1016/j.ejmech.2018.03.003. [Epub ahead of print]

90. Kailin Yu# ,Xuesong Liu#, Zongru Jiang#, Chen Hu#, Fengming Zou#, Cheng Chen, Juan Ge, Jiaxin Wu, Xiaochuan Liu, Aoli Wang, Wenliang Wang, Wenchao Wang, Ziping Qi, Beilei Wang, Li Wang, Hezhong Yan, Jiaoxue Wang, Tao Ren, Jun Tang*, Qingsong Liu*, Jing Liu*. Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs). Oncotarget. 2017 Nov 15. doi: 10.18632/oncotarget.22624. [Epub ahead of print]

89. Hua Jiang#, Hongbin He, Yun Chen, Wei Huang, Jinbo Cheng, Jin Ye, Aoli Wang, Jinhui Tao, Chao Wang, Qingsong Liu, Tengchuan Jin, Wei Jiang, Xianming Deng, Rongbin Zhou*. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017 Oct 11. doi: 10.1084/jem.20171419. [Epub ahead of print]

88. Aoli Wang#, Xixiang Li#, Cheng Chen#, Hong Wu#, Ziping Qi#, Chen Hu#, Kailin Yu, Jiaxin Wu, Juan Liu, Xiaochuan Liu, Zhenquan Hu, Wei Wang, Wenliang Wang, Wenchao Wang, Li Wang, Beilei Wang, Qingwang Liu, Lili Li, Jian Ge, Tao Ren, Shanchun Zhang, Ruixiang Xia*, Jing Liu*, and Qingsong Liu*. Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d] pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML. J. Med. Chem. 2017 Sep 28. doi: 10.1021/acs.jmedchem.7b00840. [Epub ahead of print]

87. Yongfei Chen#, Jiaxin Wu#, Aoli Wang#, Ziping Qi#, Taoshan Jiang#, Cheng Chen, Fengming Zou, Chen Hu, Wei Wang, Hong Wu, Zhenquan Hu, Wenchao Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Qingsong Liu*, Jing Liu*. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC. Eur J Med Chem. 2017 Aug 18;139:674-697. doi: 10.1016/j.ejmech.2017.08.035. [Epub ahead of print]

86. Kwok-Kin Wong, Yan Liu, Yuyang Li, Xiaoen Wang, Feiyang Liu, Peng Gao, Max M. Quinn, Fei Li, Ashley A. Merlino, Cyril H. Benes, Qingsong Liu and Nathanael S. Gray. Gemcitabine and Chk1 inhibitor AZD7762 synergistically suppress the growth of Lkb1-deficient lung adenocarcinoma. Cancer Res. 2017,Jul 28. pii: canres.0567.2017. doi: 10.1158/0008-5472.CAN-17-0567. [Epub ahead of print]

85. Beilei Wang#, Yuanxin Deng#, Yongfei Chen#, Kailin Yu, Aoli Wang, Qianmao Liang, Wei Wang, Cheng Chen, Hong Wu, Chen Hu, Weili Miao, Wooyoung Hur, Wenchao Wang, Zhenquan Hu, Ellen L. Weisberg, Jinhua Wang, Tao Ren, Yinsheng Wang, Nathanael S. Gray, Qingsong Liu*, Jing Liu*. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors. Eur. J. Med. Chem. 2017,Available online 9 June 2017. doi: 10.1016/j.ejmech.2017.06.016. [Epub ahead of print]

84. Tao Hu#, Xiaoxue Yuan#, Rongcai Ye#, Huiqiao Zhoua, Jun Lina, Chuanhai Zhang, Hanlin Zhang, Gang Wei, Meng Dong, Yuanyuan Huang, Wonchung Lime, Qingsong Liu, Hyuek Jong Lee*, Wanzhu Jin*. Brown adipose tissue activation by rutin ameliorates polycystic ovary syndrome in rat. J Nutr Biochem. 2017, Apr 22; 47: 21-28. doi: 10.1016/j.jnutbio.2017.04.012. [Epub ahead of print]

83. Chen Hu#, Aoli Wang#, Hong Wu#, Ziping Qi#, Xixiang Li#, Xiao-E Yan#, Cheng Chen, Kailin Yu, Fengming Zou, Wenchao Wang, Wei Wang, Jiaxin Wu, Juan Liu, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, Qingsong Liu.* Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode. Oncotarget 2017, 8(11): 18359-18372. doi: 10.18632/oncotarget.15443

82. Zheng Zhao, Qingsong Liu, Spencer Bliven, Lei Xie*, Philip E. Bourne*. Determining cysteines available for covalent inhibition across the human kinome. J. Med. Chem. 2017. doi: 10.1021/acs.jmedchem.6b01815

81. Hong Wu#, Qiong Huang#, Ziping Qi#, Yongfei Chen#, Aoli Wang, Cheng Chen, Qianmao Liang, Jinghua Wang, Wensheng Chen, Jin Dong, Kailin Yu, Chen Hu, Wenchao Wang, Xiaochuan Liu, Xiaoxiang Li, Nathanael S. Gray, Jing Liu*, Wei Wei*, Qingsong Liu*. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Scientific Reports 2017, doi: 10.1038/s41598-017-00482-4

80. Aoli Wang#, Xixiang Li#, Hong Wu#, Fengming Zou#, Xiao-E Yan#, Cheng Chen, Chen Hu, Kailin Yu, Wenchao Wang, Peng Zhao, Jiaxin Wu, Ziping Qi, Wei Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, Qingsong Liu*. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy) phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutants Kinase Inhibitor with a Distinct Binding Mode. J. Med. Chem. 2017. 10.1021/acs.jmedchem.6b01907

79. Juanjuan Liu, Xingxing Yang, Binhua Li, Junjun Wang, Wenchao Wang, Jing Liu, Qingsong Liu, Xin Zhang*. STK16 regulates actin dynamics to control Golgi organization and cell cycle. Scientific Reports 2017, 7: 44607. doi: 10.1038/srep44607.

78. Qianmao Liang#, Yongfei Chen#, Kailin Yu#, Cheng Chen#, Shouxiang Zhang, Aoli Wang, Wei Wang, Hong Wu, Xiaochuan Liu, Beilei Wang, Li Wang, Zhenquan Hu, Wenchao Wang, Tao Ren, Shanchun Zhang, Qingsong Liu*, Cai-Hong Yun*, Jing Liu*. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. Eur. J. Med. Chem. 2017, 131: 107-125. doi: 10.1016/j.ejmech.2017.03.001.

77. Yanke Liang, Melissanne De Wispelaere, Margot Carocci, Qingsong Liu, Jinhua Wang, Priscilla L. Yang*, Nathanael S Gray*. Structure-Activity Relationship study of QL47 - a Broad-spectrum Antiviral agent. ACS Med. Chem. Lett. 2017, 8: 344-349. doi: 10.1021/acsmedchemlett.7b00008.

76. Xiaofei Liang#, Fengchao Lv#, Beilei Wang#, Kailin Yu#, Hong Wu, Ziping Qi, Zongru Jiang, Cheng Chen, Aoli Wang, Weili Miao, Wenchao Wang, Zhenquan Hu, Juan Liu, Xiaochuan Liu, Zheng Zhao, Li Wang, Shanchun Zhang, Zi Ye, Chu Wang, Tao Ren, Yinsheng Wang, Qingsong Liu*, and Jing Liu*. Discovery of 2-((3-acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. J. Med. Chem. 2017, 60(5):1793-1816. doi:？10.1021/acs.jmedchem.6b01413.

75. Wu R, Sun JG, Wang JQ, Li B, Qingsong Liu, Ning G, Jin W, Yuan Z*. c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice. Diabetologia 2017, Jan 10. doi: 10.1007/s00125-016-4202-2.

74. Yifei Yang, Yuan Zhang, LingYun Yang, Leilei Zhao, Lianghui Si, Huibin Zhang, Qingsong Liu, Jinpei Zhou*. Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity. Bioorg. Chem. 2017, 70:126-132. doi: 10.1016/j.bioorg.2016.12.002.

73. de Wispelaere M, Carocci M, Liang Y, Qingsong Liu, Sun E, Vetter ML, Wang J, Gray NS, Yang PL.Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Res. 2017, 139: 171-179. doi: 10.1016/j.antiviral.2016.12.017.

72. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Ziping Qi, Cheng Chen, Kailin Yu, Chen Hu, Shuang Qi, Wenchao Wang, Zhenquan Hu, Juan Liu, Wei Wang, Li Wang, Qianmao Liang, Shanchun Zhang, Tao Ren, Qingsong Liu*,Jing Liu*. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J. Med. Chem. 2017, 60(1): 273-289. doi: 10.1021/acs.jmedchem.6b01290.

71. Xiaoxue Yuan#, Gang Wei#, Yilin You#,Yuanyuan Huang, Hyuek Jong Lee,Meng Dong, Jun Lin, Tao Hu, Hanlin Zhang,Chuanhai Zhang, Huiqiao Zhou,Rongcai Ye, Xiaolong Qi, Baiqiang Zhai,Weidong Huang,Shunai Liu,Wen Xie, Qingsong Liu, Xiaomeng Liu,Chengbi Cui,Donghao Li,Jicheng Zhan,Jun Cheng,Zengqiang Yuan, Wanzhu Jin. Rutin ameliorates obesity through brown fat activation. FASEB J. 2017, 31(1): 333-345. doi: 10.1096/fj.201600459RR.